Scientists discover new subtypes of blood cancer

A new model with DNA and RNA sequencing data has made it possible to identify new subtypes of a Cancer blood test called multiple myeloma and advance possible specific treatments, notes a study published in “Science Advances.”

SIGHT: A new test uses tiny worms to detect pancreatic cancer

The research team, led by Mount Sinai Hospital (United States), created a computational model called the Multiple Myeloma Patient Similarity Network (MM-PSN) and identified specific genes and genetic alterations responsible for these disease subtypes.

The study used the integration and analysis of multiple data types to create the MM-PSN, and the genes identified in the analysis included

SIGHT: Only 5% of women in Lima and Callao had a mammogram in the pandemic

Lead research author Alessandro Lagana said these findings “Have immediate implications” for the development of new precision medicine tools and clinical trials, as targeted and immunological based on their genomic and transcriptomic profiles.

Lagana considered that these studies are “fundamental” to advance in the understanding of the pathology of myeloma and “Pave the way for future research on drug reuse approaches targeting new therapies tailored to

SIGHT: Palm oil foods promote cancer metastasis, study warns

The researchers believe that the MM-PSN captures the complexity of multiple myeloma by associating patients with very similar DNA and RNA profiles. To create the MM-PSN, they analyzed five types of data obtained from DNA and RNA sequencing of 655 patients with newly diagnosed multiple myeloma.

The MM-PSN analysis identified three main groups and twelve subgroups enriched by different genetic and molecular characteristics, revealing some of the previously defined diseases, which are chromosomal abnormalities.

One of the major findings of the MM-PSN, according to the authors, is that an abnormality in one area of ​​chromosome 1 is the most important individual genetic variant associated with a high risk of relapse; the study suggests staging myeloma.

In addition, they identified new classes of high-risk patients beyond current classifications in multiple myeloma, including one of patients with a higher risk of relapse and lower overall survival, and another that is often associated with more favorable outcomes.

• A new test uses tiny worms to detect pancreatic cancer
• Only 5% of women in Lima and Callao had a mammogram in the pandemic
• Palm oil foods promote cancer metastasis, study warns
• Breast cancer vaccine clinical trials begin
• Breast Cancer: 10 Questions You Should Ask Your Doctor After Your Diagnosis
• Breast cancer in Peru: symptoms of the neoplasm that most affects women in the country
• Breast cancer: how often should I have a mammogram?
• Breast cancer in men: “The saddest thing is that it is detected in already advanced lesions”
• COVID-19 | Dogs and cats can become infected and suffer from heart problems
• How does molnupiravir, the first approved pill against COVID-19, work?
• How does the Pfizer pill that reduces the 89% risk of death from COVID-19 work?

Follow us on twitter:

!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);

.

Deshawn